Across TCGA pan-cancer cohorts, SULT1C2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SULT1C2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SULT1C2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SULT1C2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SULT1C2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.925	0.775	.004	51	view →
CCRCC	DFS	Tertile	All	1.000	0.492	.004	31	view →
LUAD	OS	Median	All	0.609	0.842	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SULT1C2 tumor-vs-normal RNA expression · all SULT1C2 data types